Close
Novotech
Jabsco PureFlo 21 Single Use

Velesco Pharma set for clinical manufacturing capacity expansion

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

eschbach Unveils Shiftconnector Activity Scheduler

New feature helps pharma manufacturing teams streamline daily production...

Clinical Trial Patient Recruitment and Site Selection

Maximizing the speed and quality of drug development requires a data-driven approach to patient enrollment and site identification, where precision analytics meet operational excellence in the 2026 clinical landscape.

Global Clinical Trials with Local Expertise in 2026

Navigating the complexities of multi-region clinical research requires a balance of global oversight and deep local knowledge to ensure regulatory compliance and efficient patient recruitment across international sites.
- Advertisement -

Pharmaceutical development and clinical manufacturing expert, Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan.

The new building will feature expanded processing suite space to provide enhanced cGMP clinical trial material capabilities. This facility will be supported by Velesco Pharma’s existing QC release and stability testing laboratory also located in Wixom. It will replace and consolidate the company’s existing manufacturing site in Kalamazoo, MI.

As part of the expansion, the company has continued to  invest in its growing team  with the recent promotion of two senior leaders. Peter Angus has moved into the role of Vice President of Research while Lisa Crandall is now Vice President of Development. Both have been with Velesco Pharma since its inception.

Founded in 2007, Velesco Pharma supports early and later stage drug development through contract analytical and drug formulation services, along with cGMP clinical supplies offering a full range of non-sterile dosage forms.

Dave Barnes, Velesco Pharma’s CEO: “This investment in new space and increase in our capacity will enable us to meet growing client demands for cGMP clinical manufacturing services while still maintaining our science-focus and flexible approach to client projects.

“Our team forged their careers in big pharma R&D and bring a wealth of expertise to the table. This experience combined with our personalized and agile approach makes us an ideal choice for clients in the critical early and later stage drug development phases.

“As a business we have always placed great emphasis on adding scientific value to the drug development process and this continues to be central to our ethos as we expand and move forward.”

The new facility is set to be fully operational by the end of this year.

For more information on Velesco Pharma visit  http://www.velescopharma.com

About Velesco Pharmaceutical Services

Velesco Pharma was formed by former big pharma R&D colleagues and focuses on supporting early and later stage drug development. Velesco provides fast and cost-effective contract analytical development and drug formulation services along with cGMP clinical supplies offering a full range of non-sterile dosage forms. The team offers personalized project management, state-of-the-art facilities and an experienced laboratory staff leading to comprehensive research relationships.

Latest stories

Related stories

eschbach Unveils Shiftconnector Activity Scheduler

New feature helps pharma manufacturing teams streamline daily production...

Clinical Trial Patient Recruitment and Site Selection

Maximizing the speed and quality of drug development requires a data-driven approach to patient enrollment and site identification, where precision analytics meet operational excellence in the 2026 clinical landscape.

Global Clinical Trials with Local Expertise in 2026

Navigating the complexities of multi-region clinical research requires a balance of global oversight and deep local knowledge to ensure regulatory compliance and efficient patient recruitment across international sites.

Adaptive CRO Models in Clinical Development Strategy

Explore the evolution of flexible clinical research organization frameworks that use real-time data to adjust trial parameters, reduce uncertainty, and optimize outcomes for global biotech innovation in 2026.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »